Sell-Side Research

The analysts’ opinions, built into your answer

Sleuth reads sell-side research from 35+ banks and research firms and puts each analyst’s forecasts, timelines, and views into the dataset for your question. Click any value to open the report it came from and read it in full.

Read between the lines of every analyst’s view

Analysts put their forecasts, timelines, and theses in long notes. Sleuth pulls out the numbers and views you need and lines them up next to the clinical and deal data for the same program.

Consensus forecasts

Sleuth gathers recent notes on a drug or company and rolls the estimates into one consensus, with each analyst’s number and the full range beside it.

Readout and launch timing

Sleuth puts the dates analysts expect for readouts, filings, and launches next to what the company itself has said.

Each analyst’s view of an asset

Sleuth lines up each analyst’s price target, valuation, and thesis next to the trials and deals for the same asset, so you can weigh the bull case against the bear case.

From global banks to small-cap specialists

Research from global and US healthcare banks, European brokers, independent analysts, and consulting firms, with archives back to 2017.

35+

Research providers

Banks, brokers, and independent research firms.

500K+

Sell-side reports

Searchable in Sleuth, and open to read in full.

48 hours

From publication to Sleuth

Sleuth adds notes from many providers sooner.

Global investment banks

Large-cap pharma and biotech coverage

US healthcare and mid-market banks

Small- and mid-cap biotech coverage

European brokers

European pharma and biotech coverage

Independent and sponsored research

Research on small-cap and non-US-listed biotechs

Consulting and industry research

Industry reports and sector analysis

China’s domestic brokers

Translated into English and searchable with the rest of our China coverage.

What’s in the reports

Initiations and company deep dives

Earnings previews and recaps

Therapeutic area primers

Conference takeaways

KOL calls and physician surveys

Drug-level sales forecasts and consensus

Price targets and valuation models

M&A and licensing commentary

Ask us for the full list

In every plan, with no bank relationship needed

You don’t need a research subscription or an account with each bank. Every plan includes every report, free to search and read.

Read it in full

Open any report in Sleuth and read the whole thing, as often as you like.

Search all of it

Search every report by drug, company, or topic, and jump straight to the pages that match.

Keep what you build

Download the datasets, charts, and decks built from the reports. The reports stay in Sleuth.

Use it everywhere

Run a project in Studio, or in Claude, ChatGPT, Copilot, or other AI tools, and Sleuth uses the same research.

Example

Every analyst’s view of the same question, side by side

Ask what analysts expect after Keytruda loses US patent protection in 2028, and Sleuth reads the 26 notes that cover it. Each analyst’s stance, view of subcutaneous Keytruda, and main risk goes in its own column, so you can see where they agree and where they diverge.

Global bank

January 6, 2026

Date

Bank

Stance

Subcutaneous Keytruda

Main risk

Feb 2026

Global bank

Bullish

Small gain; IV combos limit it

Patent to 2029 not certain

Jan 2026

Global bank

Bullish

Keeps ~65% of sales by 2030

Faster biosimilar erosion

Oct 2025

US healthcare bank

Bullish

30–40% switch in two years

Unclear replacement plan

Sep 2025

Independent

Bullish

Some protection until 2039

US patent loss, 46% of revenue

May 2025

Global bank

Not stated

Little biosimilar protection

Biosimilars and IRA pricing

May 2025

US healthcare bank

Not stated

Up to 40% switch in two years

Halozyme patent royalties

Dec 2024

Global bank

Neutral

Slows erosion, can’t stop it

IRA pricing and biosimilars

Global bank

January 6, 2026

Bank

Subcutaneous Keytruda

Global bank

Small gain; IV combos limit it

Global bank

Keeps ~65% of sales by 2030

US healthcare bank

30–40% switch in two years

Independent

Some protection until 2039

Global bank

Little biosimilar protection

US healthcare bank

Up to 40% in two years

Global bank

Slows erosion, can’t stop it

Where analysts agree

11 of the 19 notes that name a main risk point to the 2028 patent loss or how fast biosimilars take share.

Where they diverge

One bank expects subcutaneous Keytruda to keep about 65% of sales by 2030. Another says it won’t do much against biosimilars.

Where they look next

Four of the five notes that pick a top replacement point to the Verona deal and its COPD drug, Ohtuvayre.

Start with a question you’d ask an analyst

Pick a drug class, an asset, or a company you follow, fill in the brackets, and Sleuth builds the table.

Drug class

“What are analysts saying about [drug class]? Show each one’s stance, thesis, peak sales view, and the catalysts they’re watching.”

Asset

“Pull every analyst’s peak sales estimate for [asset], with the consensus, the range, and the date of each note.”

Company

“When do analysts expect [company]’s next readouts and filings, and what do they say would change their view?”

See what analysts think of your field

Set up in Claude, ChatGPT, or Copilot